Combination of topiramate and empagliflozin is considered a good option for treatment of obesity

Abstract

Introduction: The incidence of obesity has risen very much in the latest decades in which more than 30% of peoples are considered obese [1]. It is evidenced that genetics has a great impact on obesity occurrence; all in all, the risk of getting obesity in the future is linked to many factors like sedentary lifestyle, type of diet [4]. Aside from decreasing blood glucose, empagliflozin can lead to a reduction of weight due to the loss of calories by excretion of glucose [17]. Research papers also discuss the weight reducing effect of topiramate and demonstrated that this effect is dependent on the dose of the drug and duration of treatment [24].Objectives: The aim was to show if combination of topiramate and empagliflozine have the greatest weight decreasing effect in comparison to each drug alone and to placebo. Design: Randomised, placebo controlled trial, 6 month trial. Materials and Methods: 200 obese patients were randomized into 4 parallel groups. 4 groups of patients with obesity had been monitored in a private clinic, each group 50 patient’s number, with 35 females and 15 males after written consent from all patients. Result: The results show that both topiramate and empagliflozine have weight loss effect if used alone with significant p value which is 0.0480 with topiramate and 0.0048 in empagliflozine and the greatest weight loss effect if used in combination with p value less than 0.0001. Conclusion: Combination of topiramate and empagliflozin show a considerable reduction of body weight and so is considered as an option for treatment of obesity.